Loomis Sayles & Co. L P Has $10.42 Million Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Loomis Sayles & Co. L P trimmed its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 3.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 174,617 shares of the specialty pharmaceutical company’s stock after selling 6,831 shares during the quarter. Loomis Sayles & Co. L P’s holdings in ANI Pharmaceuticals were worth $10,418,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ANIP. Vanguard Group Inc. raised its holdings in shares of ANI Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company’s stock worth $90,314,000 after acquiring an additional 17,460 shares during the last quarter. O Shaughnessy Asset Management LLC purchased a new position in shares of ANI Pharmaceuticals during the first quarter valued at approximately $218,000. CANADA LIFE ASSURANCE Co boosted its position in shares of ANI Pharmaceuticals by 7.5% during the first quarter. CANADA LIFE ASSURANCE Co now owns 13,036 shares of the specialty pharmaceutical company’s stock valued at $900,000 after buying an additional 909 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in ANI Pharmaceuticals during the first quarter worth $289,000. Finally, California State Teachers Retirement System lifted its stake in ANI Pharmaceuticals by 1.5% during the 1st quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock valued at $1,118,000 after acquiring an additional 233 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Piper Sandler initiated coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price for the company. Raymond James lifted their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. Finally, StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $77.33.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the sale, the chief executive officer now owns 370,378 shares in the company, valued at $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 33,981 shares of company stock worth $1,970,066 over the last quarter. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $59.39 on Thursday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock has a fifty day simple moving average of $58.32 and a two-hundred day simple moving average of $60.76. ANI Pharmaceuticals, Inc. has a 1-year low of $48.20 and a 1-year high of $70.81. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -105.20 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same quarter in the prior year, the company earned $1.05 EPS. The firm’s quarterly revenue was up 12.5% compared to the same quarter last year. Analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.